加味没竭汤治疗原发性痛经的临床研究—对前列腺素及相关因素的影响

用加味没竭汤治疗原发性痛经６３例，并与消炎痛治疗者３２例作为对照。经３个月治疗，加味没竭汤组近期治愈率４１．３％，消炎痛组为１５．６％，两组间差异显著（Ｐ＜０．０５）。加味没竭汤可明显降低经血中ＰＧＦ２α、ＰＧＥ２的含量及比值，显著降低外周血黄体中期Ｅ２的含量，显著升高黄体末期孕酮含量。分析３３例经血ＰＧＦ２α，ＰＧＥ２含量与疼痛程度呈正相关。     

犀角地黄汤治疗儿童过敏性紫癜45例

以清热凉血为主,采用犀角地黄汤加减治疗儿童过敏性紫癜45例,治愈39例,好转4例,无效2例,有效率95.6%,疗效满意。     

半夏泻心汤加减治疗消化性溃疡60例疗效观察

消化性溃疡是临床常见病,笔者1994年以来采用半夏泻心汤加减治疗消化性溃疡60例,并与西药雷尼替丁胶囊治疗30例对照,疗效满意,报告如下。1临床资料1.1一般资料1994年以来在我院门诊及病房经纤维胃镜检查确诊为消化性溃疡(PU)的患者90例。按顺序随机分为2组,治疗组60例,其中门诊15例,住院45例;男38例,女22例;年龄18～70岁,平均37.6岁;病程1a以内12例,1～5a31例,5～10a11例,10a以上6例;其中胃溃疡(GU)22例,十二指肠溃疡(DU)29例,复合溃疡(CU)9例,并发出血5例。对照组30例,门诊8例,住院22例;男17例,女13例;年龄20～69岁,平均38.9岁;病程1a…     

清热祛瘀汤治疗药流产后出血

目的：评价清热祛瘀汤治疗药流产后出血疗效。方法：将停经≤49天的健康正常早孕妇女随机分3组，每组50例，组Ⅰ：药流产后即服诺氟沙星0.2g，3／日×4;组Ⅱ：西药同组1，在第1～3天服清热祛瘀汤;组Ⅲ：西药同组Ⅰ，第5天起不管孕囊是否排出加服清热祛瘀汤×5天。结果：组Ⅱ孕囊排出时间最短，直径较大，与其它二组相比，有显著差异（P＜0.05）;其恶心、呕吐发生率最低，具极显著差异（P＜0.01）。组Ⅲ流产后阴道出血量最少，出血持续时间最短，与组Ⅰ相比具极显著差异（P＜0.01）。结论：清热祛瘀汤对促进孕囊的排出，减少药流后出血等副反应是良好的。     

桂枝汤的药理学研究 五、加味、减味桂枝汤和桂枝汤的药理作用比较

比较了桂枝汤和桂枝去芍药汤、桂枝加桂汤、桂枝加芍药汤的实验药理作用差别,发现四方均能抑制流感病毒性肺炎、提高感染小鼠的网状内皮系统廓清能力,抑制皮肤迟发性超敏反应,作用均以桂枝汤最强,其次为桂枝加桂汤。桂枝汤、桂枝加桂和桂枝加芍药汤具有镇静作用,以桂枝加桂汤最强。桂枝加芍药汤、桂枝加桂汤和桂枝汤依次有镇痛作用。四方对正常肠蠕动功能无明显有规律的影响,但均能使亢进的肠蠕动抑制。实验结果与《伤寒论》对四方所述解表、调和营卫,治胸满、脉促,奔豚气和腹满时痛的主证大体吻合。     

桂枝汤的药理学研究——三、对小鼠非特异性屏障机能的影响

流感病毒所致小鼠病毒性肺炎,随着病程逐步加重,肺指数值上升,单核巨噬细胞系统的吞噬功能受抑,病鼠的心、肝、脾、肾、胸腺、肾上腺等重要器官也逐日减重。给病鼠以相当于人的临床剂量的桂枝汤能明显对抗上述改变,但桂枝汤对正常小鼠无明显影响这一结果提示RES功能可能与祖国医学的“营卫”有某些关联。     

炙甘草汤含药血清对兔心肌细胞瞬间外向钾电流的影响

目的 用血清药理学的方法研究炙甘草汤含药血清对兔心肌细胞瞬间外向钾电流（ho）的影响。方法 进行单个心室肌细胞的分离和膜片钳全细胞记录,将心室肌细胞分为对照组、空白血清组及5％、10%、20％、40%含药血清组,分别以普通细胞外液及加入上述不同浓度血清的细胞外液进行灌流,检测不同浓度含药血清对I10的影响。结果 含药血清可抑制I10,5％、10%、20%、40%含药血清分别将I10峰值（PA／PF）从（16．1±1．4）降至（13．9±1．5）、（11．8±1．9）、（8．3±1．5）、（8．2±1．2）,洗脱后其作用可消除。结论 炙甘草汤含药血清可抑制l。,且呈浓度依赖性作用增强,可能是炙甘草汤抗心律失常作用的机理。     

蒿芩清胆汤治疗系统性红斑狼疮活动期临床观察

目的观察蒿芩清胆汤治疗系统性红斑狼疮（SLE）活动期的疗效和安全性.方法选取SLE患者120例,随机分为两组,治疗组用蒿芩清胆汤和泼尼松,对照组用泼尼松和环磷酰胺,疗程3个月.观察治疗前后SLE活动指数（SLEDAI）及各项免疫指标,血尿常规、肝肾功能及其他不良反应发生情况.结果治疗组和对照组总有效率分别为81.67%（49/60例）、76.67%（46/60例）,两组比较差异无显著性.两组在改善SLEDAI、血沉（ESR）、C3、24h尿蛋白定量、抗dsDNA抗体方面均取得满意效果,治疗组未发现明显不良反应.结论蒿芩清胆汤治疗SLE活动期疗效显著,安全性好.     

Clinical study of Jiawei Huangqi Guizhi Wuwu Decoction in preventing and treating peripheral neuro-sensory toxicity caused by oxaliplatin

Objective: To evaluate the efficacy of Jiawei Huangqi Guizhi Wuwu Decoction (JHGWD) in treating neuro-sensory toxicity induced by oxaliplatin.Methods: A randomized controlled self-crossover trial was performed. Thirty-one patients were randomly divided into AB and BA groups. Patients in A cycle belonged to the treated group, who were treated with chemotherapy combined with oxaliplatin plus JHGWD. Patients in B cycle belonged to the control group and were treated with chemotherapy alone. The peripheral neuro-sensory toxicity was observed and analyzed.Results: The main neurotoxicity was cold-induced paresthesia after the use of oxaliplatin, which included hyperaesthesia, chill, anaesthesia in the extremities, electrified sensation, formication, foreign body sensation and pain that might be exacerbated by exposure to cold. Twenty patients (64.5%) suffered from neuro-sensory toxicity in the treated group and 27 cases (87. 1%) in the control group. Symptoms were more serious and lasted longer in the control group than those in the treated group (P<0.01).Conclusion: JHGWD could prevent and reduce the occurence and intensity of acute peripheral neuro-sensory toxicity caused by oxaliplatin.     

Clinical study on Ganbi decoction in treating antituberculotic agent-caused liver injury

Objective: To study the effect and mechanism of Ganbi decoction (GBD) in treating patients with antituberculotic agent caused liver injury (ATB-LI).Methods: One hundred and twenty-eight patients with ATB-LI were randomly assigned to the treated group (n = 66) and the control group (n = 62) with the envelop method. Meanwhile, 60 healthy persons were selected as the healthy control group. The treated group was treated by GBD one dose every day with the constituents modified depending on patients’ symptoms, and the control group was treated with glucuronolactone tablets and inosine injection. One week was taken as one treatment course. The changes of clinical syndromes, physical signs, T-lymphycyte sub-groups and serum level of nitric oxide (NO) were observed before and after treatment and the recovery time of liver function was recorded. The outcome was compared with that in the healthy control group.Results: In the treated group, 28 patients (42.4%) were cured, 30 (45.5%) improved and 8 (12.1%) ineffectively cured, the total effective rate being 87.9% (58/66). In the control group, 17 patients (27.4%) were cured, 24 (38.7%) improved, and 21 (33.9%) ineffectively cured, the total effective rate being 66. 1 % (41/62). The total effective rate in the treated group was significantly higher than that in the control group (P< 0. 05). Liver function was improved in both groups, recovery time in the treated group was 12.0 ±7.0 days, which was significantly shorter than that in the control group (16.0 ±8.0 days), showing significant difference between the two groups (P< 0.05). The levels of CD3, CD4 and CD8 were significantly higher and level of NO significantly lower in the two groups of patients than those in the healthy control group (P< 0.05), but these parameters were improved more significantly in the treated group after treatment, when compared with those before treatment or with those in the control group, all showing significant difference (P< 0.05).Conclusion: GBD could prevent ATB-LI, and its mechanism could be by way of reducing NO production induced by endotoxin of macrophage and stimulating the proliferation of T-lymphycyte to elevate immunity.